ArticleBrain and behavior2025
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Acute Exercise (flADex): Protocol for a Randomized Crossover Trial.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) is a leading cause of disability worldwide. Alterations in cerebral blood flow (CBF) and AD blood biomarkers are fundamental at early stages of AD. Exercise shows promise in delaying physiological changes, but its mechanisms for enhancing brain health remain unclear. flADex aims to examine the acute effects of different exercise types on CBF and blood biomarkers in older adults. This protocol describes the methodology and rationale of flADex.
methodsflADex is a counterbalanced crossover trial in 20 older adults, aged 68-83 years old, with negative brain amyloid status (< 12 centiloid) who are APOEε4 noncarriers. Participants will complete a 30-min session of each condition in a randomized order: (i) moderate-intensity aerobic exercise (60%-70% age-predicted maximal heart rate), (ii) moderate-intensity resistance exercise (rating of perceived exertion: 4-6 points out of 10), and (iii) resting condition. Changes in CBF are the primary outcome and will be assessed by magnetic resonance imaging using pseudo-continuous arterial spin labeling at pre- and at 3 timepoints post-condition (starting at 20, 27, 34 min). Secondary outcomes are biomarkers of AD pathology and neurodegeneration (Aβ42, Aβ40, p-tau217, p-tau181, BD-tau, GFAP, NfL) and growth factors (BDNF, IGF-1), measured through blood samples collected at pre- and post-condition (at 3, 50, 70 min). Moreover, cognitive outcomes and mood status will be measured pre- and post-condition.
conclusionflADex will highlight the acute effects of different exercise types on CBF and biomarkers before beta-amyloid accumulation. Acute effects on CBF dynamics and blood biomarkers are expected to be greater with aerobic than resistance exercise when compared to resting. CBF is expected to vary by brain region, and biomarkers to fluctuate dynamically postexercise. This will provide critical insights into exercise's impact on vascular and molecular pathways associated with AD pathology and potential recommendations for standardized blood sampling to enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.